Top 5 Healthcare Technology Stocks To Own For 2015

Top 5 Healthcare Technology Stocks To Own For 2015: EXACT Sciences Corporation(EXAS)

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect each of the four stages of colorectal cancer, as well as pre-cancerous lesions. Its test includes proprietary and patented methods, which isolate and analyze the trace amounts of human DNA that are shed into stool every day from the exfoliation of cells that line the colon. The company?s Cologuard test is also used to detect blood in stool, utilizing an antibody-based fecal immunochemical test. It has a strategic alliance agreement with LabCorp under which it licenses its patents and patent applications relating to the stool-based colorectal cancer screening technology to LabCorp; a collaboration, license, and purchase agreement with Genzyme Corporation to d eliver intellectual property improvements through licenses; and a license agreement with MAYO Foundation for medical education and research. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Advisors' Opinion:

• [By David Williamson]

  Exact Sciences' (NASDAQ: EXAS  ) phase 3 trial for its colon cancer detection test passed, but the stock dropped 20%. What gives? In this video, David Williamson goes into the details of Exact Sciences' DNA-based test. The overall effectiveness of the Cologuard test was 92%. However, the detection rate was 42%, less than colonoscopy, and the 87% overall accuracy rate leads to a higher false positive rate than most doctors would like to see. Is Exact Sciences doomed? Not really -- it has $100 million in the bank. It may be a takeover target, and David sees Intuitive Surgical (NASDAQ: ISRG  ) as a possible buyer.

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Exact Sciences (NASDAQ: EXAS) were down on the last session of 2013, falling 5.50 percent to $11.60 despite little news on the name.

• [By John Udovich]

  Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small capsArray BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) andMetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important newsfor investors this week or in recent weeks. Consider the following:

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-healthcare-technology-stocks-to-own-for-2015-2.html